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The PARTNER trial
Thomas L. Forbes, MD, London, Ontario, CanadaAn update of the Placement of AoRTic TraNscathetER
Valve (PARTNER) Trial was recently presented at the Late
Breaking Trials section of the 2010 Transcatheter Cardio-
vascular Therapeutics Conference (Washington, DC, Sep-
tember 21-25, 2010).1
The Trial is designed as two parallel randomized studies
comparing transcatheter aortic valve implantation (TAVI)
with standard surgical repair in high risk patients (n 700),
or with standard medical therapy in high risk inoperable
patients (n 358). It is the latter study, in inoperable high
risk patients that was reported at the Transcatheter Cardio-
vascular Therapeutics Conference. Primary endpoints in-
clude all-cause mortality and repeat hospitalization, in ad-
dition to stroke, major vascular complications, quality of
life, and cost-effectiveness and echocardiography assess-
ments of valve function. Twenty-one sites from the United
States, Canada, and Germany enrolled patients in the inop-
erable arm of the Trial. The study device is the Sapien-THV
(Edwards Lifesciences, Irvine, Calif), which comes in 23
and 26mm valve sizes and is delivered via a 22 or 24 French
delivery system. For the inoperable arm of the study, the
main inclusion criteria were severe calcific aortic stenosis
(echocardiography derived valve area of 0.8 cm2, mean
gradient 40 mm Hg, or jet velocity 4.0 m/s) and an
expected risk of death or irreversible morbidity of50% as
determined by a cardiologist and two surgeons. Some of
the exclusion criteria included bicuspid aortic valves, il-
iofemoral occlusive disease that would preclude safe sheath
insertion, severe left ventricular dysfunction, and end-stage
renal failure.
Equal numbers of patients (n  179 in each) were
enrolled in the TAVI and standard treatment groups of the
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(mean age over 80 in both groups) who were similar in
both groups other than standard therapy patients having a
slightly higher incidence of pulmonary disease (52.5% vs
41.3%; P .04) and atrial fibrillation (48.8% vs 32.9%; P
.04), and TAVI patients having a slightly higher incidence
of porcelain aorta (19% vs 11.2%; P  .05). Baseline echo-
cardiography characteristics of valve morphology and ven-
tricular function were similar between the two groups. Six
patients (3.4%) in the TAVI group did not receive the valve
due to death prior to the procedure (two patients), unsuc-
cessful femoral access (two patients), and intraprocedure
annulus measurements that were too large (two patients).
During the first 24 hours following TAVI there were two
deaths (1.1%), three major strokes (1.7%), one case of valve
embolization (0.6%), and two patients who required mul-
tiple valve implants (1.1%). Thirty-day mortality follow-
ing TAVI was 6.4%. Despite being deemed inoperable,
17 patients in the standard therapy group did receive an
aortic valve replacement with a 47% mortality rate at 1
year.
When compared with standard medical therapy, TAVI
patients did have more frequent complications at 30 days,
includingmajor vascular complications (16.2% vs 1.1%; P
.0001) and major strokes (5.0% vs 1.1%; P  .06). How-
ever, at 1 year, TAVI did result in a reduction in all-cause
mortality (30.7% vs 49.7%; P  .0004), cardiovascular
related mortality (19.6% vs 41.9%; P  .0001), and com-
bined all-cause mortality and repeat hospitalization (42.5%
vs 70.4%; P  .0001). There was a higher 1-year rate of all
stroke or transient ischemic attack in the TAVI group
(10.6% vs 4.5%; P  .04). Echocardiography follow up
revealed a reduction in mean gradients in TAVI patients
that did not change during 1-year follow up, and fre-
quently par avalvular regurgitation that rarely required
treatment.
The PARTNER Investigators conclude that TAVI
should be the new standard of care for patients with aortic
stenosis who are too high risk for surgery. They propose
that newer generation devices will reduce procedure related
complications, and that long-term clinical and echocardi-
ography surveillance is necessary following TAVI to deter-
mine device and procedure durability.
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The PARTNER Investigators report the 1-year results
of the inoperable arm of the Trial comparing TAVI and
standard medical therapy. This could be seen as the TAVI
version of the EndoVascular Aneurysm Repair-2 Trial for
endovascular aneurysm repair of patients that are too high
risk for open repair. The PARTNER investigators have
concluded that these inoperable high risk individuals do
benefit from TAVI, with lower mortality rates and im-
proved valvular anatomy compared with medical therapy.
The outcomes regarding the TAVI versus operative therapy
arm of the Trial are pending.
This Trial is of interest to vascular surgeons for a
number of reasons. It represents a further technological
advance in catheter-related cardiovascular interventions.
Vascular surgeons with expertise in thoracic endovascular
repairs can certainly see technological similarities between
these transcatheter aortic valves and thoracic stent grafts.
Could a mating of these technologies be far off? When will
we see a commercially available device permitting an endo-
vascular Bentall procedure for acute type A aortic dissec-
tions? Device development along these lines is inevitable,
and is one of the reasons vascular surgeons should be
interested, and involved, in these programs.In addition, vascular surgeons have experience with
transfemoral introduction of large sheath delivery systems,
and the challenges and complications related to them.
Innovative techniques have been developed to circumvent
hostile aortoiliac anatomy including surgical or internal
conduits, the use of alternative arterial access arteries (such
as the aorta or carotid arteries), and even transapical deliv-
ery.2 This is an important body of knowledge and skill set
that vascular surgeons can contribute to transfemoral aortic
valve programs that can at the very least result in fewer
access-related complications, but can also lead to improve-
ments in technique and device and delivery system refine-
ment.
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